The read at a glance
Computed from the FY2025 annual filing. Full history and the components behind each score are in the app.
- Distress risk · Altman Z-Score -1.12 — distress zone — historically elevated failure riskWatch
- Earnings-manipulation signal · Beneish M -1.94 — no flag raisedOK
- Earnings quality 59/100 — worth a closer lookWatch
Where the revenue comes from
Fiscal 2025, as ARS Pharmaceuticals, Inc. reports it. History and quarterly detail are in the app.
- Product$72.2M
- Revenue Under Collaboration Agreements$9.7M
- Revenue Under Supply Agreements$2.4M
Leadership changes
From ARS Pharmaceuticals, Inc.'s own filings, the day they're filed.
- Richard Lowenthal · member · departureeff. 2026-07-15
- Sarina Tanimoto · Chief Medical Officer · departureeff. 2026-07-15
- Richard Lowenthal · director · appointmenteff. 2026-07-06
Latest filings
- 8-K · Company announcement2026-08-13
- 10-Q · Quarterly report2026-08-13
- 8-K · Company announcement2026-07-17
- 8-K · Company announcement2026-07-07
- 8-K · Company announcement2026-06-25
In the full recordFree for 14 days
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about ARS Pharmaceuticals, Inc., every answer cited to the official filings🔒
- The Intelligence Brief — added when ARS Pharmaceuticals, Inc.'s brief passes our SEC-figure check🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.